DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis

Information source: Teva Pharmaceutical Industries
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Relapsing Remitting Multiple Sclerosis

Phase: Phase 4

Status: Completed

Sponsored by: Teva Pharmaceutical Industries

Official(s) and/or principal investigator(s):
Lillian Pardo, MD, Study Director, Affiliation: Teva Neuroscience, Inc.

Summary

It is thought that treating Multiple Sclerosis with Novantrone for a short period of time prior to treatment with Copaxone may enhance the onset effect of Copaxone.

Clinical Details

Official title: A Multi-Centered, Two Arm, Open Label Extension Study (to Protocol NC-100) to Evaluate the Long-Term Safety and Efficacy of Short-Term Induction Treatment With Mitoxantrone (NovantroneŽ) Preceding Treatment With Glatiramer Acetate (CopaxoneŽ) vs. Chronic Treatment With Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis

Study design: Observational Model: Cohort, Time Perspective: Prospective

Eligibility

Minimum age: 20 Years. Maximum age: 57 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Participation & completion of the NC-100 Clinical Trial.

- Able and willing to sign an Informed Consent.

Exclusion Criteria: none

Locations and Contacts

Additional Information

For more information about Teva Neuroscience

Starting date: October 2005
Last updated: April 27, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017